Previous Article | Next Article 
Journal of Clinical Microbiology, March 1998, p. 783-787, Vol. 36, No. 3
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Biochemical and Pathogenic Properties of
Shewanella alga and Shewanella
putrefaciens
Shideh
Khashe and
J. Michael
Janda*
Microbial Diseases Laboratory, Division of
Communicable Disease Control, California Department of Health
Services, Berkeley, California 94704-1011
Received 10 October 1997/Returned for modification 24 November
1997/Accepted 15 December 1997
 |
ABSTRACT |
We characterized 49 strains of Shewanella spp. from
clinical (n = 31) and nonhuman (n = 18) sources. Most Shewanella alga organisms (Gilardi biovar
2; Centers for Disease Control and Prevention [CDC] biotype 2)
originated from clinical material (92%), failed to produce acid from
carbohydrates other than D-ribose, and were biochemically
and enzymatically fairly homogeneous. In contrast, Shewanella
putrefaciens organisms (Gilardi biovars 1 and 3; CDC biotype 1)
were more often associated with nonhuman sources (70%), were able to
utilize a number of sugars (sucrose, L-arabinose, and
maltose), and were found to exhibit wider variations in biochemical characteristics; three biotypes within S. putrefaciens were
detected. Notable differences between the two species in enzymatic
activity, determined with the API-ZYM system (bioMérieux,
Hazelwood, Mo.), and cellular fatty acid profiles, determined by the
MIDI system (Microbial ID Inc., Newark, Del.), were also detected.
Pathogenicity studies of mice indicate that S. alga appears
to be the more virulent species, possibly due to the production of a
hemolytic substance.
 |
INTRODUCTION |
The taxon Shewanella
putrefaciens ("Pseudomonas putrefaciens") comprises
a group of gram-negative oxidative and nonoxidative bacilli whose chief
phenotypic attribute is the production of hydrogen sulfide gas
(H2S) on TSI slants (22). Although S. putrefaciens has been implicated occasionally as a human pathogen,
it is most frequently recovered from nonhuman sources, including
aquatic reservoirs (marine, freshwater, and sewage), natural energy
reserves (oil and gas), soil, and fish, poultry, dairy, and beef
products (14, 18, 20, 21). Most human isolates of
S. putrefaciens occur as part of a mixed bacterial
flora, clouding their clinical significance. However, a number of
monomicrobic illnesses due to S. putrefaciens have been
documented and include bacteremia, soft tissue infections, and otitis
media (1, 2, 4, 13).
For over two decades, it has been known that S. putrefaciens is a genetically heterogeneous species. These
conclusions are based upon the wide variation in G+C content (44 to 54 mol%), results of DNA-DNA reassociation studies, and
numerical taxonomy investigations (14, 17, 18, 20, 21). As
late as the 1980s, Gilardi (6) recognized three distinct
biovars within S. putrefaciens, while the Centers for
Disease Control and Prevention (CDC) (22) recognized two
biotypes based upon carbohydrate oxidation patterns and growth on
salmonella-shigella (SS) medium and nutrient agar containing high salt
(~6%) concentrations. In 1990, Simidu et al. (19)
proposed the name Shewanella alga for a
tetrodotoxin-producing isolate recovered from red algae. Subsequent to
this publication, Nozue and colleagues (15) found that
strains of S. putrefaciens with high G+C contents (52 to 54 mol%) were genetically related to S. alga and
not to the type strain of S. putrefaciens (ATCC 8071).
Furthermore, the latter study found that all S. alga
strains produced a hemolytic reaction on sheep blood agar while
S. putrefaciens isolates lacked this activity.
Of 40 clinical isolates of S. putrefaciens reidentified
by Nozue and others (15), 33 (83%) were found to be
S. alga based upon DNA homology values and
phenotypic criteria. Domínguez et al. (5) later
reported the first two Danish cases of S. alga bacteremia, which had originally been mistakenly attributed to S. putrefaciens. A follow-up 1997 systematic
investigation of 76 Shewanella strains found that 16 of 19 human isolates (84%) resided within the S. alga group,
based upon various taxonomic criteria including 16S rRNA
sequencing, ribotyping, and whole-cell protein profiles
(21). These studies suggest that S. alga may be the predominant human pathogen within the genus.
Presently, it is unclear how easy it is to distinguish S. putrefaciens from S. alga in the clinical
laboratory and whether or not differences in host tropism do occur and
correlate with pathogenic characteristics and overt virulence. In light
of these questions, we have analyzed the biochemical and enzymatic
capabilities of 49 Shewanella strains from diverse sources
(human and nonhuman) to address these issues and have performed
pathogenicity studies on representative strains from each group. These
studies serve as the basis of this report.
 |
MATERIALS AND METHODS |
Bacterial strains.
Forty-nine strains of
Shewanella spp. (human [n = 31] and
nonhuman [n = 18]) were investigated in this study.
Five of these strains were cultures submitted to the Microbial Diseases
Laboratory for identification. Two reference strains (ATCC 8071 and
ATCC 49138) were obtained from the American Type Culture Collection (Rockville, Md.). The remaining 42 reference or wild-type strains were
kindly provided by the following persons: A. Carnahan (Baltimore, Md.),
A. Chipman (West Sacramento, Calif.), J. Graf (Bern, Switzerland), C. Kaysner (Bothell, Wash.), V. Knight (New Brunswick, N.J.), D. Lies
(Milwaukee, Wis.), V. Pünter (Zurich, Switzerland), and T. Robin
(New York, N.Y.). Most of these strains were received as S. putrefaciens. Working cultures were maintained in motility deeps
at room temperature; typically, these isolates produced an orangish
discoloration at the surfaces of these deeps upon prolonged storage.
All assays were performed at 35°C, with the exception of eight
strains recovered from Lake Michigan, which grew poorly or failed to
grow at elevated temperatures; these strains were tested at 25°C.
Identification.
Isolates that were motile, had oxidative
metabolisms, were oxidase and catalase positive, ornithine
decarboxylase positive, and DNase positive, and produced
H2S on triple sugar iron slants within 72 h of
incubation were identified as belonging to the phenospecies
S. putrefaciens. Several
Shewanella strains failed to grow on DNase
test agar (Difco Laboratories, Detroit, Mich.), and six isolates were
nonmotile. All other reactions were uniformly positive for the 49 Shewanella strains studied. The biovar and biotype of each isolate were determined according to Gilardi
(6) and Weyant et al. (22), respectively, based
on acid production from sucrose and maltose, growth on SS agar, and
growth in the presence of 6.5% NaCl. Species designations were
determined by the criteria of Nozue et al. (15) by using the
following tests: hemolysis on sheep blood agar, growth at 42°C,
growth on nutrient agar containing 6.5% NaCl, growth on SS agar, and
acid production from maltose and L-arabinose. Five strains
each of S. alga and S. putrefaciens of
clinical origin were also tested on the API 20E (bioMérieux,
Hazelwood, Mo.), API NFT (bioMérieux), RapID NF Plus (Innovative
Diagnostic Systems, Norcross, Ga.), and Vitek (bioMérieux)
systems. All tests were performed according to the manufacturers'
instructions.
Routine biochemical test results were read daily for 72 h;
oxidation of various carbohydrates was assessed in Difco O/F medium after 7 days of incubation. Gluconate oxidation was determined only at
48 h, as previously described (10). Enzymatic plate assay results were read daily for 7 days; appropriate positive and
negative control strains were included for each assay. All of these
test procedures have been described previously (8, 11, 16).
Some additional enzymatic activities (2 h), gelatinase activity (3 days), and tartrate utilization (5 days) were determined with Wee-Tab
tablets or gelatin strips (Key Scientific Products, Roundrock, Tex.).
Phenotypic characterization.
Seventeen
Shewanella strains (S. alga
[n = 8] and S. putrefaciens
[n = 9]) were evaluated further for production of a
number of enzymatic activities with the API-ZYM test
(bioMérieux), according to the manufacturer's instructions.
Relative activity was defined as the summation of numerical values for
each isolate divided by the total number of strains tested for each
species (8). Similarly, the cellular fatty acid profiles for
14 Shewanella strains (S. alga
[n = 7] and S. putrefaciens
[n = 7]) were determined by the MIDI microbial
identification system (Microbial ID Inc., Newark, Del.).
Virulence-associated factors and resistance markers.
Ten
Shewanella strains (S. alga
[n = 5] and S. putrefaciens
[n = 5]) were evaluated for potential
virulence-associated characteristics, including resistance markers to
select antimicrobial agents. MICs of penicillin, ampicillin, and
tetracycline were determined for each strain by using the AB Biodisk E
test (Remel, Lenexa, Kans.), as previously described (11).
Hemolytic activity was tested by plate and broth assays and an agar
overlay method; a strain of Edwardsiella tarda expressing a
cell-associated hemolysin served as a positive control (9).
The adhesive, invasive, and cytotoxic capabilities of each
Shewanella isolate were evaluated with HEp-2 cell monolayers prepared in chamber slides (Lab Tek; Miles Laboratory, Naperville, Ill.), as previously described (7). The relative pathogenicity of each S. alga and S. putrefaciens strain was determined by 50% lethal dose
(LD50) assays with female Swiss Webster mice (12).
 |
RESULTS |
Biotyping of Shewanella isolates according
to two separate schemes provided similar results (Table
1). Most clinical isolates (74%)
belonged to Gilardi biovar 2 (CDC biotype 2), being sucrose and maltose
negative while growing on SS agar and on media containing high
NaCl concentrations. The only major difference noted between the
Gilardi classification scheme (6) and that of Weyant et al.
(22) was that biovar 3 isolates (sucrose, maltose, SS, and NaCl negative) were ungrouped by the CDC biotyping system. In contrast
to the human isolates, biovar 1 (CDC biotype 1) predominated (67%)
among nonhuman strains. These strains typically produced acid from
maltose and/or sucrose and failed to grow on high salt-containing or SS
agar. Based upon the recent taxonomic proposals of Nozue and others
(15), biovar 2 (CDC biotype 2) strains would be identified as S. alga while all biovar 1 (CDC biotype 1) and 6 of
7 biovar 3 strains would be designated S. putrefaciens;
the remaining biovar 3 strain was subsequently identified as
S. alga. Clinically, S. alga was found
to predominate (77%), while the majority of nonhuman isolates (89%)
were confirmed to be S. putrefaciens (Table 1).
All 10 Shewanella isolates, when tested on the
API 20E, API NFT, RapID NF Plus, and Vitek systems, were identified as
S. putrefaciens, with one exception. Four of five
S. putrefaciens isolates produced unacceptable profile
numbers on the API 20E system (no. 0602026 and 0602006); the fifth
strain generated a rare biotype number for S. putrefaciens. All S. alga strains yielded
excellent identification as S. putrefaciens on the API
20E. The API NFT system identified all 10 Shewanella isolates as S. putrefaciens with good to excellent identifications, with one
exception, also an S. putrefaciens strain (low
discriminatory value, 48 h). RapID NF Plus identified all 10 Shewanella isolates as S. putrefaciens, with 99.9% accuracy. Similarly, all strains were
identified by Vitek (97 to 99% accuracy) as S. putrefaciens, although three S. putrefaciens
strains required 5 to 9 h of incubation before final
identification, in contrast to the 4-h results for the other 7 strains.
Carbohydrate reactions (arabinose and maltose) on the API 20E, API NFT,
and Vitek systems, however, do permit most strains to be correctly
assigned to the relevant taxa (S. putrefaciens and
S. alga) if read manually after final identifications
as S. putrefaciens.
Comparison of the biochemical and enzymatic properties of
Shewanella species revealed a number of
differences (Table 2). Hemolysis on sheep blood agar, as
reported by Nozue et al. (15), was detected in all
S. alga strains but only in a couple of S. putrefaciens isolates. Most S. alga strains
exhibited this phenotype only after prolonged incubation (48 to 72 h), and the area of hemolysis was often irregular and difficult to
detect. Other activities previously found to aid in the separation of
S. alga and S. putrefaciens, such as
growth at 42°C, growth on media containing high salt (6.5%) concentrations, and acid production from L-arabinose,
sucrose, and maltose, were confirmed. We found a substantially larger
number of S. putrefaciens strains that grew on SS agar
than previously reported; most of these originated from nonhuman
sources. With the exception of ribose, production of acid from
carbohydrate oxidation was uniquely associated with S. putrefaciens. Sugar patterns, however, varied considerably among
these isolates, with some being arabinose, maltose, and sucrose
positive while others were positive for maltose only or were
asaccharolytic (biovar 3 strains). Several new enzymatic activities
were detected among select Shewanella isolates
that to our knowledge have not been previously reported. These included
tyrosinase, alkylsulfatase, chitinase, and elastase activities
(Table 2); most of these enzymes were found in nonhuman isolates of
S. putrefaciens. Most S. alga and
S. putrefaciens strains produced a siderophore, as
determined by Chrome Azurol S assays. This activity was weak, and five
isolates (three S. alga and two S. putrefaciens isolates) failed to grow on this medium.
Select Shewanella isolates that grew well at
35°C were further characterized for enzymatic activity by using
API-ZYM (Table 3) and for cellular fatty
acid profiles with the MIDI system. Of the nine substrates attacked by
one or both Shewanella species with API-ZYM,
higher overall activities for seven of these enzymes were associated
with S. alga. The single activity found to be stronger
in S. putrefaciens was valine arylamidase, although
this activity was extremely weak even in these strains. Both species produced uniformly strong alkaline phosphatase activity. An additional observation was that all S. alga strains consistently
produced eight of these nine enzymes, the only exception being valine
arylamidase. In contrast, S. putrefaciens was more
heterogeneous, with four of the nine enzymes detected being not
universally present in all isolates. Analysis of 14 Shewanella strains indicated that the
predominant fatty acids were i-15:0, 17:1
8c, and 16:0; some strains
produced large amounts of 16:1
7c (9 to 18%), while others produced
negligible quantities. While most fatty acid peaks were fairly
consistent among S. alga and S. putrefaciens strains tested, several differences were noted (Table
4). Higher mean values of pentadecanoic
acid and cis-9-heptadecenoic acid (17:1
8c) were noted for
S. alga, while the converse held true for S. putrefaciens regarding hexadecanoic and dodecanoic acids. For
hexadecanoic acid, no overlap in the total fatty acid range between
S. alga and S. putrefaciens was
observed; for pentadecanoic acid and 17:1
8c, only one S. putrefaciens or S. alga isolate produced a value that fell within the other's range. While no single peak was diagnostic, the use of all four peaks together clearly separated the 14 Shewanella strains into two groups along species
lines.
It was found that the 23 strains of S. putrefaciens
could be broken down into three separate groups based upon several
phenotypic characteristics (Table 5).
Group 1, which consisted of eight strains, including ATCC 8073, produced acid from maltose, sucrose, and arabinose and utilized
urocanic acid. Group 1 strains were equally divided among clinical and
nonhuman isolates. Group 2 strains (n = 6), which
included ATCC 8071, were chiefly distinguished from group 1 strains by
the inability to oxidize sucrose and maltose. Again, half of these
strains originated from clinical material. Group 3 strains
(n = 9), all of environmental origin (Lake Michigan area), differed dramatically from groups 1 and 2. They grew poorly or
failed to grow at 35°C, produced chitinase, and were nonpigmented on
L-tryptophan agar. All nine group 3 strains initially
produced
-glucosidase, but upon retesting only three strains were
consistently positive. Maltose was oxidized, but not sucrose or
arabinose. Unlike groups 1 and 2, urocanic acid was not utilized as a
source of energy.
Recently, Vogel and colleagues (21) have noted differences
between S. alga and S. putrefaciens in
their susceptibilities to certain antimicrobial agents, including
penicillin, ampicillin, and tetracycline. This, coupled with the report
linking hemolytic activity with S. alga and its
apparent association with human disease, suggests possible differences
in pathogenicity between these two species (Table
6). We therefore selected 10 strains (5 from each species) for further analysis. Although we did not notice
major differences in susceptibility to penicillin, ampicillin, and
tetracycline between these two groups based upon the susceptibility category (susceptible, intermediate, or resistant), we did notice that
the mean MICs for S. alga of penicillin, ampicillin,
and tetracycline (~200, 56, and 5.2 µg/ml, respectively) were
greater than the corresponding MICs for S. putrefaciens
(3, 1.3, and 1.1 µg/ml, respectively).
Four of five S. putrefaciens strains attached weakly
(+) to strongly (+++) (Table 6) to HEp-2 cells in adherence assays; in
contrast, no S. alga strains exhibited similar adhesive
characteristics, although four strains bound strongly to the glass
slide background. Invasive activities were not detected in any
Shewanella strain. Although a delayed hemolytic
reaction was observed on sheep blood agar for all five S. alga strains (Table 2), beta-hemolysis was not detected with the
agar overlay technique or broth assays (Table 6); control E. tarda strains were positive in 1 h in both tests. For all
five S. alga strains (and one S. putrefaciens isolate), a weak cytotoxic reaction was sometimes
observed during adhesion and invasion studies. This cytotoxic reaction
was manifested by the appearance of HEp-2 cells with abnormal cellular
morphology, including cell debris (ghosts). Differences in mouse
pathogenicity between these two species were found, however, as the
mean LD50 in Swiss Webster mice for S. alga
was 1.9 × 108 CFU, while that for S. putrefaciens was 8.4 × 108 CFU
(P < 0.02).
 |
DISCUSSION |
In agreement with previous investigators (15, 21), we
found S. alga, rather than S. putrefaciens, to be the predominant Shewanella species associated with clinical
specimens. These species were easy to distinguish from one another by
using a number of recommended phenotypic tests, such as growth at
42°C, growth in 6.5% NaCl, production of a hemolytic substance, and
utilization of various carbohydrates (Table 2). Growth on SS agar, a
differential trait noted in various studies, was found to be less
useful in the present survey, as 52% of the S. putrefaciens strains exhibited this characteristic. However, this
result may be a somewhat spurious observation, as most SS-positive
S. putrefaciens strains originated from one geographic
region (Lake Michigan and Green Bay). Although the S. alga strains typically were unable to utilize sugars, 35% of the
isolates tested produced acid from D-ribose.
Domínguez and colleagues (5) also found that two
bacteremic strains of S. alga, plus the type strain,
used D-ribose, while the type strain of S. putrefaciens did not. Thus, production of acid from
D-ribose may be a marker for S. alga
strains. Another species-associated trait was alkylsulfatase activity;
>70% of the S. putrefaciens strains elaborated this
enzyme, while only 8% of the S. alga strains were
positive. We also found the S. alga strains to produce
uniformly higher levels of enzymatic activities against a number of
substrates in the API-ZYM system (Table 3). Of nine compounds utilized
by either or both species, S. alga produced
approximately two- to threefold-higher mean enzymatic activity against
five of these substrates than did S. putrefaciens. This
suggests that isolates might be presumptively screened for species
determinations with this 4-h test, based upon the overall higher
enzymatic activity of S. alga strains. Finally, we also
noted that comparisons of fatty acid profiles of the two species
revealed quantitative differences in four fatty acids that may be
useful in species determination (Table 4). However, both of the latter
sets of results need confirmation by evaluation of a larger number of
isolates of each species.
A reflection of the phenotypic diversity found within S. putrefaciens was the recognition of three distinct biogroups
within the species (Table 5). These biogroups were distinguished from one another by a number of phenotypic tests, including several new
differential characteristics (
-glucosidase, chitinase, and urocanic
acid). Nozue and others (15) found that S. putrefaciens as presently defined is still heterogeneous at the
DNA level, with at least three detectable genomospecies based upon DNA
homology values. Clearly, further work needs to be undertaken to link
specific phenotypic markers to each of these hybridization groups.
Why S. alga appears to be the predominant
Shewanella species associated with human
infections remains unclear. Results of limited pathogenicity studies on
select Shewanella strains suggest that adherence
to epithelial cells is not a major determinant. However, we did notice
significant differences between S. alga and
S. putrefaciens in mouse LD50 studies,
suggesting a possible explanation for the preferential association of
the former species with human disease. One attractive explanation for
this observation is the hemolytic reaction produced by virtually all
S. alga strains, and some authors have suggested
possible exotoxin involvement in S. putrefaciens
cellulitis (3). Although we were able to detect this
beta-hemolytic-type reaction upon prolonged incubation of isolates on
sheep blood agar (48 to 72 h), other methods traditionally positive for the presence of a cytolytic toxin (beta-hemolysin), such
as broth, agar overlay, and epithelial cell cytotoxicity assays, were
either uniformly negative or weakly positive at best. Such results
raise considerable questions as to the nature of this hemolytic
reaction and whether or not it is caused by a true beta-hemolysin.
Regardless, there appears to be increasing evidence that, between
S. alga and S. putrefaciens,
S. alga causes the most human illnesses and that
significant differences exist between these two species regarding
resistance to antimicrobial agents, mouse pathogenicity, and
certain virulence factors (hemolysis and adhesion). Whether these
factors translate into true in vivo differences with respect to disease
spectrum, pathogenicity, and therapy remains to be determined.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Microbial
Diseases Laboratory, 2151 Berkeley Way, Berkeley, CA 94704-1011. Phone:
(510) 540-2242. Fax: (510) 540-2374. E-mail:
jjanda{at}hw1.cahwnet.gov.
 |
REFERENCES |
| 1.
|
Brink, A. J.,
A. van Straten, and A. J. van Rensburg.
1995.
Shewanella (Pseudomonas) putrefaciens bacteremia.
Clin. Infect. Dis.
20:1327-1332[Medline].
|
| 2.
|
Butt, A. A.,
J. Figueroa, and D. H. Martin.
1997.
Ocular infection caused by three unusual marine organisms.
Clin. Infect. Dis.
24:470.
|
| 3.
|
Chen, S. C. A.,
R. H. Lawrence,
D. R. Packlam, and T. C. Sorrell.
1991.
Cellulitis due to Pseudomonas putrefaciens: possible production of exotoxins.
Rev. Infect. Dis.
13:642-643[Medline].
|
| 4.
|
Chen, Y.-S.,
Y.-C. Liu,
M.-Y. Yen,
J.-H. Wang,
J.-H. Wang,
S.-R. Wann, and D.-L. Cheng.
1997.
Skin and soft-tissue manifestations of Shewanella putrefaciens infection.
Clin. Infect. Dis.
25:225-229[Medline].
|
| 5.
|
Domínguez, H.,
B. F. Vogel,
L. Gram,
S. Hoffmann, and S. Schaebel.
1996.
Shewanella alga bacteremia in two patients with lower leg ulcers.
Clin. Infect. Dis.
22:1036-1039[Medline].
|
| 6.
|
Gilardi, G. L.
1985.
Cultural and biochemical aspects for identification of glucose-nonfermenting gram-negative rods, p. 17-84.
In
G. L. Gilardi (ed.), Nonfermentative gram-negative rods. Marcel Dekker, Inc., New York, N.Y.
|
| 7.
|
Graves, M.,
T. Robin,
A. M. Chipman,
J. Wong,
S. Khashe, and J. M. Janda.
1997.
Four additional cases of Burkholderia gladioli infection with microbiological correlates and review.
Clin. Infect. Dis.
25:838-842[Medline].
|
| 8.
|
Janda, J. M.
1985.
Biochemical and exoenzymatic properties of Aeromonas species.
Diagn. Microbiol. Infect. Dis.
3:223-232[Medline].
|
| 9.
|
Janda, J. M., and S. L. Abbott.
1993.
Expression of an iron-regulated hemolysin by Edwardsiella tarda.
FEMS Microbiol. Lett.
111:275-280[Medline].
|
| 10.
|
Janda, J. M.,
S. L. Abbott,
S. Khashe,
G. H. Kellogg, and T. Shimada.
1996.
Further studies on biochemical characteristics and serologic properties of the genus Aeromonas.
J. Clin. Microbiol.
34:1930-1933[Abstract].
|
| 11.
|
Janda, J. M.,
S. L. Abbott,
S. Khashe, and T. Robin.
1996.
Biochemical investigations of biogroups and subspecies of Morganella morganii.
J. Clin. Microbiol.
34:108-113[Abstract].
|
| 12.
|
Janda, J. M., and R. P. Kokka.
1991.
The pathogenicity of Aeromonas strains relative to genospecies and phenospecies identification.
FEMS Microbiol. Lett.
90:29-34.
|
| 13.
|
Kim, J. H.,
R. A. Cooper,
K. E. Welty-Wolf,
L. J. Harrell,
P. Zwadyk, and M. E. Klotman.
1989.
Pseudomonas putrefaciens bacteremia.
Rev. Infect. Dis.
11:97-104[Medline].
|
| 14.
|
Levin, R. E.
1972.
Correlation of DNA base composition and metabolism of Pseudomonas putrefaciens isolates from food, human clinical specimens, and other sources.
Antonie Leeuwenhoek
38:121-127.
|
| 15.
|
Nozue, H.,
T. Hayashi,
Y. Hashimoto,
T. Ezaki,
K. Hamasaki,
K. Ohwada, and Y. Terawaki.
1992.
Isolation and characterization of Shewanella alga from human clinical specimens and emendation of the description of S. alga Simidu et al., 1990, 335.
Int. J. Syst. Bacteriol.
42:628-634[Abstract/Free Full Text].
|
| 16.
|
Oliver, J. D.,
J. E. Wear,
M. B. Thomas,
M. Warner, and K. Linder.
1986.
Production of extracellular enzymes and cytotoxicity by Vibrio vulnificus.
Diagn. Microbiol. Infect. Dis.
5:99-111[Medline].
|
| 17.
|
Owen, R. J.,
R. M. Legros, and S. P. Lapage.
1978.
Base composition, size and sequence similarities of genome deoxyribonucleic acids from clinical isolates of Pseudomonas putrefaciens.
J. Gen. Microbiol.
104:127-138[Abstract/Free Full Text].
|
| 18.
|
Semple, K. M.,
J. L. Doran, and D. S. Westlake.
1989.
DNA relatedness of oil-field isolates of Shewanella putrefaciens.
Can. J. Microbiol.
35:925-931.
|
| 19.
|
Simidu, U.,
K. Kita-Tsukamoto,
T. Yasumoto, and M. Yotsu.
1990.
Taxonomy of four marine bacterial strains that produce tetrodotoxin.
Int. J. Syst. Bacteriol.
40:331-336[Abstract/Free Full Text].
|
| 20.
|
Stenström, I.-M., and G. Molin.
1990.
Classification of the spoilage flora of fish, with special reference to Shewanella putrefaciens.
J. Appl. Bacteriol.
68:601-618[Medline].
|
| 21.
|
Vogel, B. F.,
K. Jørgensen,
H. Christensen,
J. E. Olsen, and L. Gram.
1997.
Differentiation of Shewanella putrefaciens and Shewanella alga on the basis of whole-cell protein profiles, ribotyping, phenotypic characterization, and 16S rRNA gene sequence analysis.
Appl. Environ. Microbiol.
63:2189-2199[Abstract].
|
| 22.
|
Weyant, R. S.,
C. W. Moss,
R. E. Weaver,
D. G. Hollis,
J. G. Jordan,
E. C. Cook, and M. I. Daneshvr.
1995.
Identification of unusual pathogenic gram-negative aerobic and facultatively anaerobic bacteria, 2nd ed.
Williams & Wilkins, Baltimore, Md.
|
Journal of Clinical Microbiology, March 1998, p. 783-787, Vol. 36, No. 3
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Richards, G. P., Watson, M. A., Crane, E. J. III, Burt, I. G., Bushek, D.
(2008). Shewanella and Photobacterium spp. in Oysters and Seawater from the Delaware Bay. Appl. Environ. Microbiol.
74: 3323-3327
[Abstract]
[Full Text]
-
Kim, D., Baik, K. S., Kim, M. S., Jung, B.-M., Shin, T.-S., Chung, G.-H., Rhee, M. S., Seong, C. N.
(2007). Shewanella haliotis sp. nov., isolated from the gut microflora of abalone, Haliotis discus hannai. Int. J. Syst. Evol. Microbiol.
57: 2926-2931
[Abstract]
[Full Text]
-
Kim, D.-M., Kang, C.-I., Lee, C. S., Kim, H.-B., Kim, E.-C., Kim, N. J., Oh, M.-d., Choe, K.-W.
(2006). Treatment Failure Due to Emergence of Resistance to Carbapenem during Therapy for Shewanella algae Bacteremia.. J. Clin. Microbiol.
44: 1172-1174
[Abstract]
[Full Text]
-
Botelho-Nevers, E., Gouriet, F., Rovery, C., Paris, P., Roux, V., Raoult, D., Brouqui, P.
(2005). First Case of Osteomyelitis Due to Shewanella algae. J. Clin. Microbiol.
43: 5388-5390
[Abstract]
[Full Text]
-
O'Hara, C. M.
(2005). Manual and Automated Instrumentation for Identification of Enterobacteriaceae and Other Aerobic Gram-Negative Bacilli. Clin. Microbiol. Rev.
18: 147-162
[Abstract]
[Full Text]
-
Heritier, C., Poirel, L., Nordmann, P.
(2004). Genetic and Biochemical Characterization of a Chromosome-Encoded Carbapenem-Hydrolyzing Ambler Class D {beta}-Lactamase from Shewanella algae. Antimicrob. Agents Chemother.
48: 1670-1675
[Abstract]
[Full Text]
-
Oliver, J. W.
(2003). Ochrobactrum anthropi Misidentified as Shewanella putrefaciens. J. Clin. Microbiol.
41: 4486-4486
[Full Text]
-
Pagani, L., Lang, A., Vedovelli, C., Moling, O., Rimenti, G., Pristera, R., Mian, P.
(2003). Soft Tissue Infection and Bacteremia Caused by Shewanella putrefaciens. J. Clin. Microbiol.
41: 2240-2241
[Abstract]
[Full Text]
-
Ferrandez, A., Hawkins, A. C., Summerfield, D. T., Harwood, C. S.
(2002). Cluster II che Genes from Pseudomonas aeruginosa Are Required for an Optimal Chemotactic Response. J. Bacteriol.
184: 4374-4383
[Abstract]
[Full Text]
-
Iwata, M., Tateda, K., Matsumoto, T., Furuya, N., Mizuiri, S., Yamaguchi, K.
(1999). Primary Shewanella alga Septicemia in a Patient on Hemodialysis. J. Clin. Microbiol.
37: 2104-2105
[Abstract]
[Full Text]